364 related articles for article (PubMed ID: 17430191)
21. Mediation of cell death by poly(ADP-ribose) polymerase-1.
Koh DW; Dawson TM; Dawson VL
Pharmacol Res; 2005 Jul; 52(1):5-14. PubMed ID: 15911329
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
23. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
24. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ
Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138
[TBL] [Abstract][Full Text] [Related]
25. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
27. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Decker P; Muller S
Curr Pharm Biotechnol; 2002 Sep; 3(3):275-83. PubMed ID: 12164482
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of poly(ADP-ribose) polymerase-1 in longevity.
Bürkle A; Brabeck C; Diefenbach J; Beneke S
Int J Biochem Cell Biol; 2005 May; 37(5):1043-53. PubMed ID: 15743677
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribosyl)ation and stroke.
Chiarugi A
Pharmacol Res; 2005 Jul; 52(1):15-24. PubMed ID: 15911330
[TBL] [Abstract][Full Text] [Related]
30. Role of Peroxynitrite-Induced Activation of Poly(ADP-Ribose) Polymerase (PARP) in Circulatory Shock and Related Pathological Conditions.
Islam BU; Habib S; Ali SA; Moinuddin ; Ali A
Cardiovasc Toxicol; 2017 Oct; 17(4):373-383. PubMed ID: 27990620
[TBL] [Abstract][Full Text] [Related]
31. PARP inhibitors: new tools to protect from inflammation.
Giansanti V; Donà F; Tillhon M; Scovassi AI
Biochem Pharmacol; 2010 Dec; 80(12):1869-77. PubMed ID: 20417190
[TBL] [Abstract][Full Text] [Related]
32. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Pieper AA; Verma A; Zhang J; Snyder SH
Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
[TBL] [Abstract][Full Text] [Related]
33. Novel modulators of poly(ADP-ribose) polymerase.
Szabo C; Pacher P; Swanson RA
Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
[TBL] [Abstract][Full Text] [Related]
34. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
[TBL] [Abstract][Full Text] [Related]
35. Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets.
Genovese T; Cuzzocrea S
Curr Med Chem; 2008; 15(5):477-87. PubMed ID: 18289003
[TBL] [Abstract][Full Text] [Related]
36. The antimitotic potential of PARP inhibitors, an unexplored therapeutic alternative.
Iglesias P; Costoya JA
Curr Top Med Chem; 2014; 14(20):2346-65. PubMed ID: 25434352
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Szabó C
Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
[TBL] [Abstract][Full Text] [Related]
38. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
39. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
[TBL] [Abstract][Full Text] [Related]
40. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]